Clinical Trials List
Protocol NumberES-CMSC01-A1201
Active
2023-05-01 - 2028-12-31
Phase II
Recruiting2
-
Trial Applicant
EVER SUPREME BIO TECHNOLOGY CO., LTD.
-
Sponsor
-
Trial scale
Taiwan Multiple Center
-
Update
2026/08/01
Investigators and Locations
Principal Investigator
Co-Principal Investigator
- 盧炯睿 Division of Cardiovascular Diseases
- 王宇澄 Division of Cardiovascular Diseases
- Kuan-Cheng Chang Division of Cardiovascular Diseases
- Long-Bin Jeng Division of Cardiovascular Diseases
- 梁馨月 Division of Cardiovascular Diseases
- 呂尚謁 Division of Cardiovascular Diseases
- Lien-Cheng Hsiao Division of Cardiovascular Diseases
- 張靜芬 Division of Cardiovascular Diseases
- 李庚原 Division of Cardiovascular Diseases
- 林育楷 Division of Cardiovascular Diseases
- 林晏年 Division of Cardiovascular Diseases
- Wen-Chien Cheng Division of Thoracic Medicine
- 王駿丞 Division of Cardiovascular Diseases
- 何昆霖 Division of Cardiovascular Diseases
- Po-Yen Ko Division of Cardiovascular Diseases
- 胡幃勛 Division of Cardiovascular Diseases
- 張志斌 Division of Cardiovascular Diseases
- 張家寧 Division of Cardiovascular Diseases
- Shih-Sheng Chang Division of Cardiovascular Diseases
- 張靜芬 Division of Cardiovascular Diseases
- 陳大隆 Division of Cardiovascular Diseases
- 陳琦棟 Division of Cardiovascular Diseases
- 湯文德 Division of Cardiovascular Diseases
- 黃志勤 Division of Cardiovascular Diseases
- 黃信鎰 Division of Cardiovascular Diseases
- 劉家豪 Division of Cardiovascular Diseases
- 鄭英男 Division of Cardiovascular Diseases
- 魏榮廷 Division of Cardiovascular Diseases
- 羅翊賓 Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
41 participants
-
Global
41 participants
